Long-term safety study of a medication for psychiatric disorders in children and teens
Part of Mental health clinical trials.
This study tests a combination medicine (xanomeline and trospium chloride) to see if it is safe and tolerable over a longer period for children and adolescents with psychiatric disorders, especially those with autism-related irritability. It may help families understand if this treatment can be used beyond the initial study period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must have finished the main part of a previous study (CN0120020, CN0120044, or CN0120045) without serious side effects.
- If new to the study, must have a confirmed diagnosis of autism spectrum disorder (ASD) with irritability.
- Must not have any significant risk of violent behavior, self-harm, or suicidal thoughts.
- Must not have any serious health problems (like abnormal heart, blood pressure, or physical exam findings) that would make participation unsafe.
- Must not have very high blood pressure (stage 2 hypertension).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new medicine, KarXT, can safely and effectively treat schizophrenia in adolescents. It may help teenagers who have active symptoms like hallucinations or disorganized thinking.
This study tests a new medicine (KarXT) for schizophrenia, focusing on how it affects urological (bladder and urinary) safety. You'll stop your current antipsychotic and take the study drug to see if it works well and is safe for your urinary system.
This trial looks at how well KarXT works and what side effects it might have when people with schizophrenia switch to it from their current antipsychotic medication. It may be an option for those who have started KarXT recently or who plan to switch from their current treatment.
This trial tests a new injectable form of KarXT for schizophrenia. It aims to see if the medicine is safe, tolerable, and how it works in the body.
This trial tests whether a new oral medication, KarXT, can help prevent a return of schizophrenia symptoms in people who have been stable on treatment. If you've had a hospital stay in the past year and still have some symptoms, you may be able to join.
This trial tests a new medication called KarXT for people with schizophrenia who are currently having a psychotic episode. It is for Japanese adults who have had schizophrenia before and are not in their first episode.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.